Literature DB >> 20335353

Advanced heart failure and nocturnal hypoxaemia due to central sleep apnoea are associated with increased serum erythropoietin.

Andrew D Calvin1, Virend K Somers, David P Steensma, Jose A Rio Perez, Christelle van der Walt, Jennifer M Fitz-Gibbon, Christopher G Scott, Lyle J Olson.   

Abstract

AIMS: Central sleep apnoea (CSA) and increased serum erythropoietin (EPO) concentration have each been associated with adverse prognosis in heart failure (HF) patients. The aim of this study was to examine the relationship between nocturnal hypoxaemia due to CSA and the serum EPO concentration in patients with HF. METHODS AND
RESULTS: Heart failure subjects (n = 33) and healthy controls (n = 18) underwent polysomnography (PSG) for diagnosis of CSA and identification and quantification of hypoxaemia. Blood collection for measurement of EPO was performed immediately post-PSG. For the analysis, HF subjects were dichotomized into subgroups defined by the presence or absence of CSA and by HF severity. Multivariate analyses were performed to evaluate the relationships of hypoxaemia and advanced HF to EPO concentration. Mean EPO concentration was 62% higher for HF subjects with CSA than for healthy controls (P = 0.004). The magnitude of nocturnal hypoxaemia was significantly and positively related to EPO concentration (r = 0.45, P = 0.02). Advanced HF was also significantly and positively related to EPO concentration (r = 0.43, P = 0.02). On multivariate analysis, the presence of combined nocturnal hypoxaemia and advanced HF yielded greater correlation to EPO concentration than either factor alone (r = 0.57, P = 0.04 and P = 0.05, respectively). Linear regression demonstrated that the combination of New York Heart Association Class and CSA was strongly associated with EPO concentration (P < 0.0001).
CONCLUSION: In non-anaemic HF patients, advanced HF and hypoxaemia due to CSA may each be independently associated with increased serum EPO concentration.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20335353      PMCID: PMC2844758          DOI: 10.1093/eurjhf/hfq005

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  28 in total

Review 1.  Sleep apnea and heart failure: Part II: central sleep apnea.

Authors:  T Douglas Bradley; John S Floras
Journal:  Circulation       Date:  2003-04-08       Impact factor: 29.690

2.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

3.  Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing.

Authors:  Virend K Somers; David P White; Raouf Amin; William T Abraham; Fernando Costa; Antonio Culebras; Stephen Daniels; John S Floras; Carl E Hunt; Lyle J Olson; Thomas G Pickering; Richard Russell; Mary Woo; Terry Young
Journal:  J Am Coll Cardiol       Date:  2008-08-19       Impact factor: 24.094

4.  Effects of continuous positive airway pressure on cardiovascular outcomes in heart failure patients with and without Cheyne-Stokes respiration.

Authors:  D D Sin; A G Logan; F S Fitzgerald; P P Liu; T D Bradley
Journal:  Circulation       Date:  2000-07-04       Impact factor: 29.690

5.  Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia.

Authors:  A N Vgontzas; D A Papanicolaou; E O Bixler; K Hopper; A Lotsikas; H M Lin; A Kales; G P Chrousos
Journal:  J Clin Endocrinol Metab       Date:  2000-03       Impact factor: 5.958

Review 6.  The cardiovascular effects of erythropoietin.

Authors:  Kyle J Smith; Anthony J Bleyer; William C Little; David C Sane
Journal:  Cardiovasc Res       Date:  2003-09-01       Impact factor: 10.787

7.  Effects of an angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitors on burst forming units-erythroid in chronic hemodialysis patients.

Authors:  Masayo Naito; Akira Kawashima; Takashi Akiba; Minoko Takanashi; Hiroshi Nihei
Journal:  Am J Nephrol       Date:  2003-07-31       Impact factor: 3.754

8.  Erythropoietin-induced excessive erythrocytosis activates the tissue endothelin system in mice.

Authors:  Thomas Quaschning; Frank Ruschitzka; Thomas Stallmach; Sidney Shaw; Henning Morawietz; Winfried Goettsch; Matthias Hermann; Torsten Slowinski; Franz Theuring; Berthold Hocher; Thomas F Lüscher; Max Gassmann
Journal:  FASEB J       Date:  2002-12-18       Impact factor: 5.191

9.  Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure.

Authors:  Peter van der Meer; Adriaan A Voors; Erik Lipsic; Tom D J Smilde; Wiek H van Gilst; Dirk J van Veldhuisen
Journal:  J Am Coll Cardiol       Date:  2004-07-07       Impact factor: 24.094

10.  Erythropoietin and obstructive sleep apnea.

Authors:  Mikolaj Winnicki; Abu Shamsuzzaman; Paola Lanfranchi; Valentina Accurso; Eric Olson; Diane Davison; Virend K Somers
Journal:  Am J Hypertens       Date:  2004-09       Impact factor: 2.689

View more
  4 in total

Review 1.  Biomarkers associated with obstructive sleep apnea: A scoping review.

Authors:  Graziela De Luca Canto; Camila Pachêco-Pereira; Secil Aydinoz; Paul W Major; Carlos Flores-Mir; David Gozal
Journal:  Sleep Med Rev       Date:  2014-11-28       Impact factor: 11.609

Review 2.  Diagnostic capability of biological markers in assessment of obstructive sleep apnea: a systematic review and meta-analysis.

Authors:  Graziela De Luca Canto; Camila Pachêco-Pereira; Secil Aydinoz; Paul W Major; Carlos Flores-Mir; David Gozal
Journal:  J Clin Sleep Med       Date:  2015-01-15       Impact factor: 4.062

3.  Erythropoietin, ferritin, haptoglobin, hemoglobin and transferrin receptor in metabolic syndrome: a case control study.

Authors:  Päivi Hämäläinen; Juha Saltevo; Hannu Kautiainen; Pekka Mäntyselkä; Mauno Vanhala
Journal:  Cardiovasc Diabetol       Date:  2012-09-27       Impact factor: 9.951

4.  Erythropoietin levels in patients with sleep apnea: a meta-analysis.

Authors:  Xiao-Bin Zhang; Yi-Ming Zeng; Hui-Qing Zeng; Hua-Ping Zhang; Hui-Ling Wang
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-03-09       Impact factor: 2.503

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.